Abstract

Objective: To explore the mechanism of Chuanxiong in alleviating hypoxic pulmonary hypertension in rats by inhibiting pulmonary vascular remodeling. Methods: Thirty healthy and clean male SD rats weighing (180 - 220) g were randomly divided into three groups (n = 10): normoxia group (n), hypoxia group (H) and Chuanxiong group (L). Group N was fed in normoxic environment, and the other two groups were fed in hypoxic (9% 11% O2) environment for 4 weeks, 8 h/D, 6 days a week. Rats in group L were gavaged with Ligusticum chuanxiong solution diluted with normal saline at the concentration of 300 mg/kg, and rats in group H were gavaged with equal volume of normal saline. After 4 weeks, the mean pulmonary artery pressure was measured. After pulmonary perfusion, the right ventricular free wall and left ventricle plus ventricular septum were taken to measure the right ventricular hypertrophy index. The changes of pulmonary morphology and ultrastructure were observed under light microscope. Results: Compared with group n, the average pulmonary artery pressure and right ventricular hypertrophy index in the other two groups increased, and the thickening of pulmonary vascular wall was obvious under microscope (P < 0.01); compared with group H, the above changes in group L were reduced (P < 0.05). Conclusion: Ligusticum chuanxiong can relieve pulmonary artery pressure in rats by inhibiting pulmonary vascular remodeling.

Highlights

  • Pulmonary arterial hypertension (PAH) is a group of diseases that can cause remodeling of pulmonary microvascular structure, increase pulmonary vascular resistance, and cause right heart failure, with high disability rate and mortality [1]

  • Compared with group n, the average pulmonary artery pressure and right ventricular hypertrophy index in the other two groups increased, and the thickening of pulmonary vascular wall was obvious under microscope (P < 0.01); compared with group H, the above changes in group L were reduced (P < 0.05)

  • PAH is a kind of progressive disease whose specific etiology and mechanism have not been clarified

Read more

Summary

Introduction

Pulmonary arterial hypertension (PAH) is a group of diseases that can cause remodeling of pulmonary microvascular structure, increase pulmonary vascular resistance, and cause right heart failure, with high disability rate and mortality [1]. Ligusticum chuanxiong has the effect of calcium antagonist, which can expand coronary vessels, reduce pulmonary artery pressure and achieve the purpose of treating cor pulmonale, but there are few studies on pulmonary vascular remodeling of chuanqiong at present. This experiment aims to explore whether chuanqiong can alleviate the occurrence and progress of pulmonary hypertension by inhibiting pulmonary vascular remodeling, so as to provide new treatment ideas and methods for clinical prevention and treatment of pulmonary hypertension

Experimental Grouping and Model Preparation
Measurement of Right Ventricular Hypertrophy Index in Rats
Statistical Treatment
Comparison of Right Ventricular Hypertrophy Index in Each Group
Discussion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.